Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies-Reference-Cited by-同舟云学术

Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies

Published:2016-05-03 Issue:14 Volume:122 Page:2178-2185
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Kantarjian Hagop M.¹,Stein Anthony S.²,Bargou Ralf C.³,Grande Garcia Carlos⁴,Larson Richard A.⁵,Stelljes Matthias⁶,Gökbuget Nicola⁷,Zugmaier Gerhard⁸,Benjamin Jonathan E.⁹,Zhang Alicia⁹,Jia Catherine¹⁰,Topp Max S.¹¹

Affiliation:

1. Department of Leukemia; The University of Texas MD Anderson Cancer Center; Houston Texas

2. Gehr Leukemia Center; City of Hope; Duarte California

3. Department of Internal Medicine II, Hematology/Oncology, Comprehensive Cancer Center Mainfranken; University Hospital of Würzburg; Wurzburg Germany

4. Department of Medicine, Hematology, University Hospital “12 de Octubre”; Madrid Spain

5. Department of Medicine, Hematology/Oncology; University of Chicago; Chicago Illinois

6. Department of Medicine; University of Muenster; Muenster Germany

7. Department of Medicine II; University Hospital; Frankfurt Germany

8. Amgen Research Munich GmbH; Munich Germany

9. Amgen; Thousand Oaks California

10. Amgen South San Francisco; South San Francisco California

11. Medical Clinic and Polyclinic II; University Hospital of Würzburg; Wurzburg Germany

Funder

Amgen Inc.

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference27 articles.

1. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial;Moorman;Blood.,2007

2. The challenges of managing older patients with acute lymphoblastic leukemia;Marks;Am Soc Clin Oncol Educ Book.,2015

3. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial;Sive;Br J Haematol.,2012

4. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation;Gökbuget;Blood.,2012

5. How I treat older patients with ALL;Gökbuget;Blood.,2013

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment of Relapsed Acute Lymphocytic Leukemia in Adult Patients;Current Treatment Options in Oncology;2024-06-25

2. Management of ALL in adults: 2024 ELN recommendations from a European expert panel;Blood;2024-05-09

3. Managing infectious challenges in the age of molecular‐targeted therapies for adult hematological malignancies;Transplant Infectious Disease;2024-05-02

4. Risk of Severe Infections Secondary to the Use of Targeted Therapies in Hematological Malignancies;Cureus;2024-01-10

5. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial;The Lancet Haematology;2023-06